Helix Acquisition Corp IIHLXB
HLXB
About: Helix Acquisition Corp II is a Blank check company.
0
Funds holding %
of 7,295 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
8% more capital invested
Capital invested by funds: $173M [Q4 2024] → $186M (+$13.6M) [Q1 2025]
0.22% more ownership
Funds ownership: 86.97% [Q4 2024] → 87.19% (+0.22%) [Q1 2025]
3% less funds holding
Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for HLXB.
Financial journalist opinion
Neutral
Business Wire
3 months ago
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
SOUTH SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“BBOT”), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, and Helix Acquisition Corp. II (Nasdaq: HLXB) (“Helix”), a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, today announced that they have entered into a definitive business combination a.
Neutral
Business Wire
1 year ago
Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Helix Acquisition Corp. II (Nasdaq: HLXB) (the “Company”) announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary shares which includes 2,400,000 shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The offering was priced at $10.00 per share resulting in gross proceeds of $184,000,000, before deducting underwriting discounts and commissions and other offering expenses payable.
Charts implemented using Lightweight Charts™